Pharmaceuticals, Biotechnology and Life Sciences
Denali Therapeutics will work with Sanofi on its multiple RIPK1 inhibitor molecules that could treat a range of neurological and systemic inflammatory diseases.
@ActiniumPharma moves to next stage of development for its CD33 ARC (Antibody Radiation Conjugate) Ac-225-Lintuzumab program are pivotal trial pathway for its Actimab-MDS program for Myelodysplastic Syndromes (MDS), and also in two combination trials with Venetoclax for AML.
$ATNM
Advanced Stem Cell Training Network (ASCTN), a European research consortium , has successfully bid for over €3,700,000 in funding from the European Union to create and exploit advanced cellular models of neurological disorders – notably Parkinson´s, Huntington´s and Demyelination disease – which are caused by acute or progressive loss of cells in the brain, said Plasticell Ltd, a developer of stem cell technologies and regenerative medicines, in which the company is a partner organisation
Omya, a producer of industrial minerals informed Monday about a price increase of 7 – 9% for its Calcium Carbonate products in the US and Canada, from the start of the next year.
@n4pharma with MedImmune UK, has been studying the level of immune response Nuvec can deliver when combined with a target antigen in a study using messenger RNA (mRNA) and plasmid DNA (pDNA) encoded with the standard test antigen Ovalbumin (OVA).
Spanish contract development and manufacturing organisation (CDMO) @Idifarma has begun its seventh project with Spanish biotechnology company, Palobiofarma.
LEH Pharma, a provider of revolutionary ocular implants for macular disorders, has picked Syneos Health, a fully integrated biopharmaceutical solutions organization, as its Global Clinical Development and Commercialisation Provider.
Hemogenyx and Orgenesis have entered into collaboration on the further development of Human Postnatal Hemogenic Endothelial Cell technology
Neovacs will continue the development of its IFNalpha Kinoid in South Korea with its partner Chong Kun Dang (CKD) Pharmaceutical Corp, on the basis of the licensing agreement signed in December 2015, for a potential overall value of €5M, the company said Thursday.
Sanofi and Regeneron has gotten the approval from the U.S. Food and Drug Administration (FDA) for Biologics License Application (sBLA) for Praluent Injection, a PCSK9 inhibitor.